Abstract
Background Optimizing a restriction spectrum imaging (RSI) model for the prostate could lead to improved characterization of diffusion in the prostate and better discrimination of tumors. Purpose To determine optimal apparent diffusion coefficients (ADCs) for prostate RSI models and evaluate the number of tissue compartments required to best describe diffusion in prostate tissue. Study Type Retrospective. Population/Subjects Forty-six patients who underwent an extended MRI examination for suspected prostate cancer; 23 had prostate tumors and 23 had no detectable cancer. Field strength/Sequence 3T multi-shell diffusion weighted sequence. Assessment RSI models with 2-5 tissue compartments were fit to multi-shell DWI data from the prostate to determine optimal compartmental ADCs. Signal contributions from the different tissue compartments were computed using these ADCs and compared between normal tissues (peripheral zone, transition zone, seminal vesicles) and tumors. Statistical Tests The Bayesian Information Criterion (BIC) was used to evaluate the optimality of different RSI models. Model-fitting residual (as percent variance) was recorded to assess the models' goodness-of-fit and whether it varied between anatomical regions of the prostate. Two-sample t-tests (α=0.05) were used to determine the statistical significance of any differences observed in compartmental signal-fraction between normal prostate tissue and tumors. Results The lowest BIC was observed from the 4-compartment model. Optimal ADCs for the 4 compartments were 5.2e-4, 1.9e-3, 3.0e-3, and ≫3.0e-3 mm2/s. Tumor tissue showed the largest reduction in fitting residual by increasing model order. Prostate tumors had a significantly (P≪0.05) greater proportion of signal from compartments 1 and 2 than normal tissue. Tumor conspicuity in compartment 1 increased substantially with model order. Data Conclusion Among the examined RSI models, the 4-compartment model best described the diffusion-signal characteristics of the prostate. Compartmental signal fractions revealed by such a model may improve discrimination between cancerous and benign prostate tissue.
Competing Interest Statement
Anders M Dale reports that he was a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. He receives funding through research grants from GE Healthcare to UC San Diego. The terms of these arrangements have been reviewed by and approved by UC San Diego in accordance with its conflict of interest policies.
Funding Statement
This work was supported by funding from the following sources: USAMR DoD W81XWH-17-1-0618 NIH K08 NIBIB EB026503 Prostate Cancer Foundation UC San Diego Center for Precision Radiation Medicine
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Contact the corresponding author with any inquiries regarding the data presented in this manuscript.
